Disc Medicine

IRONPhase 3

Watertown, United Statesdiscmedicine.com

Disc Medicine is a publicly traded biotech company focused on transforming the treatment landscape for hematologic diseases by targeting fundamental pathways in red blood cell biology and iron metabolism. The company has built a diversified pipeline through strategic in-licensing of clinical-stage assets from Roche, AbbVie, and Mabwell, with its lead program, bitopertin, in Phase 3 development for erythropoietic protoporphyria. With a seasoned leadership team and a clear focus on hematology, Disc Medicine aims to address significant unmet needs in both rare and common blood disorders.

Market Cap

$2.2B

Focus

AntibodiesBiologicsSmall Molecules

IRON · Stock Price

USD 58.17+15.27 (+35.59%)

Historical price data

AI Company Overview

Technology Platform

Disc Medicine's approach is centered on targeting key pathways in red blood cell biology and iron metabolism, specifically through hepcidin suppression to treat anemias and hepcidin induction to treat iron overload/polycythemia conditions.

Pipeline Snapshot

10 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
Placebo + DISC-1459	Erythropoietic Protoporphyria (EPP)	Phase 3
DISC-1459 + DISC-1459	Erythropoietic Protoporphyria	Phase 2/3
DISC-0974 + Placebo	Inflammatory Bowel Disease (IBD)	Phase 2
DISC-1459 + DISC-1459 + Placebo	Erythropoietic Protoporphyria	Phase 2
DISC-3405	Polycythemia Vera (PV)	Phase 2

Opportunities

Disc Medicine has significant growth opportunities through successful clinical development of its lead assets, particularly bitopertin for EPP/XLP (a first-in-class opportunity) and DISC-0974 for large-market anemias of inflammation.

Positive data could lead to strategic partnerships, expanded indications, and ultimately, a transition to a commercial-stage company.

Risk Factors

Key risks include clinical trial failures across its pipeline, regulatory hurdles for approval, future challenges in commercialization and competition, dependence on capital markets for funding, and obligations to partners for in-licensed assets.

The company's value is highly tied to near-term clinical readouts.

Competitive Landscape

Disc Medicine faces competition varying by indication: in EPP/XLP from dersimelagon and afamelanotide; in anemias from ESAs, HIF-PH inhibitors, luspatercept, and momelotinib; in polycythemia vera from rusfertide and standard therapies. Its differentiation lies in a focused hematology strategy and novel mechanisms targeting hepcidin and heme biosynthesis pathways.

Publications

Patents

Pipeline